Stockscreener 앱 받기
2.13
4.05%
-0.09
시간 외 거래:
2.08
-0.05
-2.35%
전일 마감가:
$2.22
열려 있는:
$2.24
하루 거래량:
130.12K
Relative Volume:
0.76
시가총액:
$56.00M
수익:
$1.79M
순이익/손실:
$-70.90M
주가수익비율:
-0.1371
EPS:
-15.54
순현금흐름:
$-34.95M
1주 성능:
-4.48%
1개월 성능:
+9.79%
6개월 성능:
-40.17%
1년 성능:
-65.65%
1일 변동 폭
$2.06
$2.25
1주일 범위
$2.0311
$2.25
52주 변동 폭
$1.26
$7.10
센티 바이오사이언시스 Stock (SNTI) Company Profile
명칭
Senti Biosciences Inc
전화
(650) 239-2030
주소
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
SNTI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
2.13 | 58.37M | 1.79M | -70.90M | -34.95M | -15.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
센티 바이오사이언시스 Stock (SNTI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-14 | 개시 | H.C. Wainwright | Buy |
| 2025-06-06 | 개시 | Laidlaw | Buy |
| 2022-10-07 | 개시 | Morgan Stanley | Equal-Weight |
센티 바이오사이언시스 주식(SNTI)의 최신 뉴스
Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.
Senti Biosciences, Inc. to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented At the American Society of Hematology Annual Meeting 2025 - marketscreener.com
Senti Biosciences, Inc. to Host Conference Call on Updated Clinical Results for SENTI-202 Prior to ASH Annual Meeting - Quiver Quantitative
Senti Bio (Nasdaq: SNTI) to host Dec. 9 webcast on updated SENTI-202 data from ASH 2025 - Stock Titan
How Senti Biosciences Inc. stock reacts to oil pricesJuly 2025 Price Swings & Capital Efficiency Focused Strategies - Newser
Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 - ADVFN
Form 8-KCurrent report - ADVFN
Check Out Senti Biosciences Inc (SNTI)’s Trade Data Rather Than the Analysts’ Views - Setenews
Senti Biosciences, Inc. (NASDAQ:SNTI) Receives $8.75 Consensus PT from Analysts - Defense World
Leerink Partners Initiates Coverage on Senti Biosciences (NASDAQ:SNTI) - Defense World
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study - MSN
Leerink Partners initiates coverage on Senti Biosciences stock with Outperform rating - Investing.com Australia
Leerink Partners Initiates Coverage of Senti Biosciences (SNTI) with Outperform Recommendation - Nasdaq
Leerink Partners initiates coverage on Senti Biosciences stock with Outperform rating By Investing.com - Investing.com South Africa
SNTI Stock Rating Update: Leerink Partners Initiates Coverage | - GuruFocus
Why Senti Biosciences Inc. stock is a must watch in 20252025 Breakouts & Breakdowns & Free Long-Term Investment Growth Plans - newser.com
Is Senti Biosciences Inc. stock vulnerable to regulatory risksJuly 2025 Closing Moves & Weekly High Return Forecasts - newser.com
Why Senti Biosciences Inc. stock could benefit from AI revolutionWeekly Gains Summary & Technical Entry and Exit Tips - newser.com
Is Senti Biosciences Inc. trending in predictive chart modelsQuarterly Market Summary & Expert Approved Momentum Ideas - newser.com
Combining machine learning predictions for Senti Biosciences Inc.Quarterly Profit Review & Weekly Breakout Stock Alerts - newser.com
How Senti Biosciences Inc. stock benefits from global expansionEarnings Risk Summary & Growth Focused Stock Reports - newser.com
Building trade automation scripts for Senti Biosciences Inc.2025 Volume Leaders & Weekly Momentum Picks - newser.com
Will Senti Biosciences Inc. stock recover faster than peersEarnings Recap Report & Technical Analysis for Trade Confirmation - newser.com
Is Senti Biosciences Inc. forming a reversal patternJuly 2025 Pullbacks & Daily Market Momentum Tracking - newser.com
Will a bounce in Senti Biosciences Inc. offer an exitEarnings Risk Report & Risk Managed Investment Entry Signals - newser.com
Bicara Therapeutics (NASDAQ:BCAX) versus Senti Biosciences (NASDAQ:SNTI) Head to Head Analysis - Defense World
센티 바이오사이언시스 (SNTI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
센티 바이오사이언시스 주식 (SNTI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lu Timothy K | CEO |
Feb 06 '25 |
Sale |
4.36 |
545 |
2,376 |
82,082 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. |
Feb 04 '25 |
Sale |
4.07 |
1,297 |
5,279 |
8,803 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. |
Feb 06 '25 |
Sale |
4.37 |
182 |
795 |
8,621 |
1.44%
0.91%
자본화:
|
볼륨(24시간):